Accession | ARO:3000488 |
Definition | Telavancin is a semi-synthetic derivative of vancomycin and is a second-generation lipoglycopeptide antibiotic. Telavancin inhibits cell wall synthesis by forming a complex with the D-Ala-D-Ala terminus of peptidoglycan precursors and preventing transglycosylation. |
SMILES | N/A |
PubChem | 3081362 |
Drug Class | glycopeptide antibiotic |
Classification | 2 ontology terms | Show |
Parent Term(s) | 1 ontology terms | Show + glycopeptide antibiotic [Drug Class] |
Sub-Term(s) | 1 ontology terms | Show + acyl-D-alanyl-D-alanine targeted_by_antibiotic |
Publications | Smith WJ and Drew RH. 2009. Drugs Today (Barc) 45(3): 159-173. Telavancin: a new lipoglycopeptide for gram-positive infections. (PMID 19436839) Charneski L, et al. 2009. Ann Pharmacother 43(5): 928-938. Telavancin: a novel lipoglycopeptide antibiotic. (PMID 19401479) Nannini EC and Stryjewski ME. 2008. Expert Opin Pharmacother 9(12): 2197-2207. A new lipoglycopeptide: telavancin. (PMID 18671473) |
Curator | Description | Most Recent Edit |
---|